SCHEMBL1502173

SCHEMBL1502173

COc1cc(N)c(Cl)cc1C(=O)NCC1CN(CC2CCN(C(=O)c3ccc(C#N)cc3)CC2)CCO1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.51
KCNH2 Q12809 3/20 0.51
MEN1 O00255 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
CYP2C9 P11712 1/20 0.51
ADRA2B P18089 1/20 0.51
HTR2C P28335 1/20 0.51
SLC6A4 P31645 1/20 0.51
CYP2C19 P33261 1/20 0.51
HTR2B P41595 1/20 0.51
KMT2A Q03164 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
DRD2 P14416 2/20 0.50
DRD4 P21917 2/20 0.50
HTR4 Q13639 12/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1502059 0.92 KCNH2 (0.54) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1502167 0.92 KCNH2 (0.55) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1501903 0.92 DRD3 (0.54) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1501968 0.92 KCNH2 (0.54) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1502045 0.92 HTR4 (0.59) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1501963 0.90 KCNH2 (0.58) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1502432 0.90 KCNH2 (0.52) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1502166 0.90 DRD3 (0.56) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1502058 0.89 KCNH2 (0.53) DRD3KCNH2MEN1LMNACYP1A2
SCHEMBL1501955 0.88 DRD3 (0.52) DRD3KCNH2MEN1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2256114-B1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAINIPPON SUMITOMO PHARMA CO (JP) 2014-06-25 EP claimed
US-7906510-B2 Amide derivative and pharmaceutical composition containing the same Dainippon Sumito Pharma Co., Ltd. (JP) 2011-03-15 US claimed
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Sumitomo Pharma Co., Ltd. (JP) 2010-09-30 US claimed
EP-2256114-B1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAINIPPON SUMITOMO PHARMA CO (JP) 2014-06-25 EP disclosed
US-7906510-B2 Amide derivative and pharmaceutical composition containing the same Dainippon Sumito Pharma Co., Ltd. (JP) 2011-03-15 US disclosed
EP-2256114-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-12-01 EP disclosed
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Sumitomo Pharma Co., Ltd. (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME HTR4, MC2R, HTR1D DRD3 270/4885KCNH2 4145/4885MEN1 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.